Company: PETVW
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001493152-25-006783
Chunk: 13

Company: PetVivo Holdings, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
 is $2.41 per share. These warrants are excluded from the weighted average number
of shares because they were considered anti-dilutive.

The
Company had 198,126 restricted stock units outstanding as of December 31, 2024, which are excluded from the weighted average number of
shares because they were considered anti-dilutive.

The
Company had 1,019,878 stock options outstanding as of December 31, 2024, with varying exercise prices ranging from $0.80 to $2.79 per
share. The weighted average exercise price for these options is $1.80 per share. These stock options are excluded from the weighted average
number of shares because they were considered anti-dilutive.

The
Company had 5,799,709 of warrants outstanding as of December 31, 2023, with varying exercise prices ranging from $1.20 to $5.63 per share.
The weighted average exercise price for these warrants is $3.89 per share. These warrants are excluded from the weighted average number
of shares because they were considered anti-dilutive.

The
Company had 166,084 restricted stock units outstanding as of December 31, 2023, which are excluded from the weighted average number of
shares because they were considered anti-dilutive.

The
Company had 1,529,788 stock options outstanding as of December 31, 2023, with varying exercise prices ranging from $1.03 to $2.79 per
share. The weighted average exercise price for these options is $2.06 per share. These stock options are excluded from the weighted average
number of shares because they were considered anti-dilutive.

The
Company uses the guidance in Accounting Standards Codification (“ASC”) 260 to determine if-converted loss per share. ASC
260 states that convertible securities should be considered exercised on the latter of the first day of the reporting period’s
quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing
diluted EPS if the effect would be anti-dilutive.

(L)
Revenue Recognition

The
Company recognizes revenue in accordance with ASC 606 “Revenue from Contracts with Customers.”

The
Company derives revenue from the sale of its pet care products directly to its veterinarian customers in the United States. The Company
recognizes revenue when performance obligations under the terms of a contract with the veterinarian customer are satisfied. Product sales